A Phase 4 interventional study of Travoprost Ophthalmic Solution 0.004% in Normal Tension Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-10-07.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004% ophthalmic solution (TRAVATAN Z®) in subjects with normal tension glaucoma.
65 studies on the registry are indexed under Low Tension Glaucoma; 9 are open to participants now.
This study's enrollment of 32 is below the median of 42 across 32 interventional studies indexed under Low Tension Glaucoma.
Browse Low Tension Glaucoma studies →Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.
Drug: Travoprost Ophthalmic Solution 0.004%
benzalkonium chloride (BAC) free
Also known as: TRAVATAN Z®
Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data at 9:00 AM from Weeks 4, 8, and 12 were pooled. A more negative change indicates a greater amount of improvement. One eye (study eye) was subject to analysis.
Time frame: Baseline (Day 0), Week 4, Week 8, Week 12
Subjects were recruited from 5 study sites located in Japan.
| Milestone | TRAVATAN Z |
|---|---|
| Started | 32 |
| Completed | 31 |
| Not completed | 1 |
| Withdrew: Change in residence | 1 |
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data at 9:00 AM from Weeks 4, 8, and 12 were pooled. A more negative change indicates a greater amount of improvement. One eye (study eye) was subject to analysis.
| mmHg | TRAVATAN Z |
|---|---|
| Baseline | 16.55 (15.88 to 17.22) |
| Change from Baseline | -3.37 (-3.90 to -2.85) |
Collected over Adverse events (AEs) were collected for the duration of the study (Sep 2013 - Jun 2014). This analysis population includes all subjects enrolled in the study, minus any subject whose safety evaluation data is all missed (1 subject).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TRAVATAN Z | — | 0/31 (0%) | 0/31 (0%) |
This analysis population includes all enrolled subjects minus any subjects with all missing data and/or critical protocol deviation/s.
| Age, Continuous(years) | TRAVATAN Z |
|---|---|
| Mean | 65.6 ± 11.1 |
| Sex: Female, Male(Participants) | TRAVATAN Z |
|---|---|
| Female | 18 |
| Male | 12 |
| Baseline IOP(mmHg) | TRAVATAN Z |
|---|---|
| 9:00 AM | 16.55 ± 1.43 |
| 1:00 PM | 15.72 ± 1.82 |
| 5:00 PM | 15.73 ± 2.17 |
The record gives a start of Sep 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost